Although much of cancer immunotherapy has historically focused on CD8+ cytotoxic T lymphocytes, accumulating evidence highlights CD4+ T cells as central coordinators of both innate and adaptive immune responses, capable of exerting direct and indirect anti-tumor effects [119, 120]. Here, CD4 is linked to neoplasm.